For patients with locoregionally advanced RET-mutated MTC, including patients with invasive nodal disease, a novel strategy of neo-adjuvant RET-specific inhibitor prior to surgical resection has been reported [61], and this approach continues to be studied in an ongoing clinical trial (NCT04759911) [62]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.